| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f3340775faa98e7d4f8802d3f3a2ef1f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-308 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 |
| filingDate |
2019-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff768d8505f76fe77c2bf8564ac4bca9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_713d1900613ff0c7b4dc13d24ce116fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be7f3ecf0089b4cff155eed2eaddd5f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c04e4ec7ea1c66e4cd4207e689c218c4 |
| publicationDate |
2019-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190088896-A |
| titleOfInvention |
PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY WITH ANTICANCER DRUGS USING CONTROL TECHNOLOGY FOR Ca2+ SIGNALING-MEDIATED EXOSOME SECRETION |
| abstract |
The present invention relates to a method for enhancing the combined administration effect of an anticancer agent by controlling the secretory ability of exosome by utilizing a calcium signal transduction mechanism control technique inside and outside the cell. The pharmaceutical composition for joint administration for prevention or treatment of cancer comprising the anticancer agent and exo secretagogue according to the present invention minimizes adverse effects by minimizing the dose of the conventional anticancer drug, The anticancer efficacy can be maximized. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021085843-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210050182-A |
| priorityDate |
2018-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |